Last updated: February 20, 2026
Vitrakvi (larotrectinib) is a targeted cancer therapy indicated for tumors with NTRK gene fusions. Its manufacturing relies on high-quality active pharmaceutical ingredients (APIs) sourced from multiple global suppliers.
Major API Suppliers for Vitrakvi
1. CordenPharma
- Location: Europe (Switzerland, Germany)
- Capabilities:
- Contract manufacturing for complex APIs.
- Focus on sterile and oligonucleotide APIs.
- Market Role:
- Supplies key intermediates and finished APIs for oncology drugs, including larotrectinib.
2. Siegfried AG
- Location: Switzerland
- Capabilities:
- API synthesis with capacity for complex small molecules.
- Extensive process development for high potency APIs.
- Market Role:
- Provides APIs for niche oncology treatments, including targeted therapies.
3. Auriga Laboratories & Contract Manufacturers
- Location: India (various units)
- Capabilities:
- Wide range of small-molecule APIs.
- Cost-effective manufacturing options.
- Market Role:
- Supplies bulk APIs for global generic and innovator companies.
4. Dr. Reddy's Laboratories
- Location: India
- Capabilities:
- Large-scale API manufacturing.
- Dose-specific API production in oncology.
- Market Role:
- Supplies APIs for generic versions and development kits.
5. WuXi AppTec
- Location: China, US
- Capabilities:
- Custom synthesis and large-scale API manufacturing.
- Supports complex chemical process development.
- Market Role:
- Provides APIs for various targeted cancer therapies.
API Manufacturing Process Overview for Larotrectinib
Larotrectinib's synthesis involves several key chemical steps:
- Preparation of heteroaryl intermediates.
- Chiral synthesis to ensure enantiomeric purity.
- Final purification to meet regulatory standards.
Major suppliers possess scalable processes aligned with GMP requirements ensuring batch-to-batch consistency.
Supply Chain Dynamics and Risks
| Aspect |
Details |
| Concentration of suppliers |
Few suppliers account for most API production capacity (domestic and international). |
| Geographical risks |
Dependence on supply chains in India, China, and Europe exposes operations to regional disruptions. |
| Regulatory status |
Suppliers hold approvals from agencies like the FDA, EMA, and PMDA. |
| Capacity expansion |
Several suppliers have announced capacity upgrades through 2023–2025. |
Regulatory and Quality Standards
Suppliers must comply with:
- Good Manufacturing Practice (GMP)
- International standards (ICH Q7 for APIs)
- Batch validation and stability testing
Leading suppliers publish detailed certificates of analysis (CoA) with every batch.
Key Takeaways
- Multiple GMP-compliant suppliers provide APIs for Vitrakvi.
- Suppliers are globally distributed, with primary sources in Europe, India, and China.
- Supply chain security is crucial due to concentration and regional risks.
- Capacity upgrades aim to meet increasing demand for larotrectinib.
FAQs
Q1: Who are the primary API manufacturers for larotrectinib?
A: CordenPharma, Siegfried AG, WuXi AppTec, Dr. Reddy's Laboratories, and Indian manufacturers.
Q2: What standards do these API suppliers adhere to?
A: They comply with GMP, ICH Q7, and other international regulatory standards.
Q3: Are there risks associated with the current API supply chain?
A: Yes. Overreliance on regional suppliers in India and China presents potential disruptions.
Q4: Have suppliers announced capacity expansions?
A: Yes. Several plan upgrades through 2023–2025 to meet global demand.
Q5: What is the role of process development in API sourcing?
A: It ensures high purity, potency, and consistent quality aligned with regulatory requirements.
References
- European Medicines Agency. (2022). Vitrakvi (larotrectinib) summary.
- U.S. Food and Drug Administration. (2021). Approved drug products with therapeutic equivalence evaluations.
- International Council for Harmonisation. (2016). Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
- CordenPharma. (2023). API manufacturing capabilities.
- WuXi AppTec. (2022). API supply chain and capacity reports.
